RT Journal Article
SR Electronic
T1 Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21257987
DO 10.1101/2021.06.01.21257987
A1 Thompson, Mark G.
A1 Burgess, Jefferey L.
A1 Naleway, Allison L.
A1 Tyner, Harmony
A1 Yoon, Sarang K.
A1 Meece, Jennifer
A1 Olsho, Lauren E.W.
A1 Caban-Martinez, Alberto J.
A1 Fowlkes, Ashley L.
A1 Lutrick, Karen
A1 Groom, Holly C.
A1 Dunnigan, Kayan
A1 Odean, Marilyn J
A1 Hegmann, Kurt
A1 Stefanski, Elisha
A1 Edwards, Laura J.
A1 Schaefer-Solle, Natasha
A1 Grant, Lauren
A1 Ellingson, Katherine
A1 Kuntz, Jennifer L.
A1 Zunie, Tnelda
A1 Thiese, Matthew S.
A1 Ivacic, Lynn
A1 Wesley, Meredith G.
A1 Lamberte, Julie Mayo
A1 Sun, Xiaoxiao
A1 Smith, Michael E.
A1 Phillips, Andrew L.
A1 Groover, Kimberly D.
A1 Yoo, Young M.
A1 Gerald, Joe K.
A1 Brown, Rachel T.
A1 Herring, Meghan K.
A1 Joseph, Gregory
A1 Beitel, Shawn
A1 Morrill, Tyler C.
A1 Mak, Josephine
A1 Rivers, Patrick
A1 Poe, Brandon P.
A1 Lynch, Brian
A1 Zhou, Ying Tao
A1 Zhang, Jing
A1 Kelleher, Anna
A1 Li, Yan
A1 Dickerson, Monica
A1 Hanson, Erika
A1 Guenther, Kyley
A1 Tong, Suxiang
A1 Bateman, Allen
A1 Reisdorf, Erik
A1 Barnes, John
A1 Azziz-Baumgartner, Eduardo
A1 Hunt, Danielle R.
A1 Arvay, Melissa L.
A1 Kutty, Preeta
A1 Fry, Alicia M.
A1 Gaglani, Manjusha
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.06.01.21257987.abstract
AB BACKGROUND Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered in real-world conditions.METHODS Prospective cohorts of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing during December 14 2020—April 10 2021. Self-collected mid-turbinate nasal swabs were tested by qualitative and quantitative reverse-transcription–polymerase-chain-reaction (RT-PCR). VE was calculated as 100%×(1−hazard ratio); adjusted VE was calculated using vaccination propensity weights and adjustments for site, occupation, and local virus circulation.RESULTS SARS-CoV-2 was detected in 204 (5.1%) participants; 16 were partially (≥14 days post-dose-1 to 13 days after dose-2) or fully (≥14 days post-dose-2) vaccinated, and 156 were unvaccinated; 32 with indeterminate status (<14 days after dose-1) were excluded. Adjusted mRNA VE of full vaccination was 91% (95% confidence interval [CI]=76%–97%) against symptomatic or asymptomatic SARS-CoV-2 infection; VE of partial vaccination was 81% (95% CI=64%-90%). Among partially or fully vaccinated participants with SARS-CoV-2 infection, mean viral RNA load (Log10 copies/mL) was 40% lower (95% CI=16%-57%), the risk of self-reported febrile COVID-19 was 58% lower (Risk Ratio=0.42, 95% CI=0.18-0.98), and 2.3 fewer days (95% CI=0.8-3.7) were spent sick in bed compared to unvaccinated infected participants.CONCLUSIONS Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infections when administered in real-world conditions and attenuated viral RNA load, febrile symptoms, and illness duration among those with breakthrough infection despite vaccination.Competing Interest StatementAllison L. Naleway reported funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work. Kurt T. Hegmann serves at the Editor of the American College of Occupational and Environmental Medicine evidence-based practice guidelines. Matthew S. These reported grants and personal fees from Reed Group and the American College of Occupational and Environmental Medicine, outside the submitted work. Other authors have reported no conflicts of interest.Funding StatementFunding provided in whole or in part by federal funds from the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention under contract numbers 75D30120R68013 awarded to Marshfield Clinic Research Laboratory, 75D30120C08379 to University of Arizona, and 75D30120C08150 awarded to Abt Associates, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the University of Arizona IRB as the single IRB for this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data will be available once all study objectives are met.